Overview

Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Pharmaceutical Solutions
Tobramycin